Decision Making in Proliferative Diabetic Retinopathy Treatment

Mary B. Kansora; Raquel Goldhardt

doi:10.1007/s40135-019-00198-w

Decision Making in Proliferative Diabetic Retinopathy Treatment

Mary B. Kansora, Raquel Goldhardt

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Purpose of Review: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. Recent Findings: For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. Summary: Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.

Original language	English (US)
Pages (from-to)	45-50
Number of pages	6
Journal	Current Ophthalmology Reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.1007/s40135-019-00198-w
State	Published - Mar 15 2019

Keywords

Aflibercept
Anti-VEGF
Bevacizumab
Intravitreal injection
Pan retinal photocoagulation
Proliferative diabetic retinopathy
Ranibizumab
Vascular endothelial growth factor

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1007/s40135-019-00198-w

Cite this

@article{6b87040837c140a0b7e8f4129d411e15,

title = "Decision Making in Proliferative Diabetic Retinopathy Treatment",

abstract = "Purpose of Review: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. Recent Findings: For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. Summary: Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.",

keywords = "Aflibercept, Anti-VEGF, Bevacizumab, Intravitreal injection, Pan retinal photocoagulation, Proliferative diabetic retinopathy, Ranibizumab, Vascular endothelial growth factor",

author = "Kansora, {Mary B.} and Raquel Goldhardt",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = mar,

day = "15",

doi = "10.1007/s40135-019-00198-w",

language = "English (US)",

volume = "7",

pages = "45--50",

journal = "Current Ophthalmology Reports",

issn = "2167-4868",

number = "1",

}

TY - JOUR

T1 - Decision Making in Proliferative Diabetic Retinopathy Treatment

AU - Kansora, Mary B.

AU - Goldhardt, Raquel

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Purpose of Review: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. Recent Findings: For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. Summary: Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.

AB - Purpose of Review: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. Recent Findings: For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. Summary: Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.

KW - Aflibercept

KW - Anti-VEGF

KW - Bevacizumab

KW - Intravitreal injection

KW - Pan retinal photocoagulation

KW - Proliferative diabetic retinopathy

KW - Ranibizumab

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85081091595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081091595&partnerID=8YFLogxK

U2 - 10.1007/s40135-019-00198-w

DO - 10.1007/s40135-019-00198-w

M3 - Review article

C2 - 31595210

AN - SCOPUS:85081091595

SN - 2167-4868

VL - 7

SP - 45

EP - 50

JO - Current Ophthalmology Reports

JF - Current Ophthalmology Reports

IS - 1

ER -

Decision Making in Proliferative Diabetic Retinopathy Treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this